Devinsu Trading Appoints Independent Director, CFO, and Company Secretary
Devinsu Trading Limited held a board meeting on May 18, 2026, approving the appointment of Mrs. Sangita Hiren Shukla as Additional Independent Director for five years, Mr. Krish Piyush Shah as CFO, and Ms. Khushi Gangwani as Company Secretary & Compliance Officer. The board also appointed Mr. Bhaveshkumar Arjunkumar Rawal as Secretarial Auditor and Mr. Akash Mehta as Internal Auditor, both for FY 2025-26 to FY 2029-30. The company subsequently disclosed its updated KMP structure to the stock exchange under Regulation 30(5) of SEBI (LODR) Regulations, 2015.

*this image is generated using AI for illustrative purposes only.
Devinsu Trading Limited convened its board meeting on May 18, 2026, to discuss and approve several key appointments. The meeting was held at the company's registered office at 2, Floor-1, Plot-90/94, Zaveri Mansion, Shaikh Memon Street, Zaveri Bazar, Kalbadevi, Mumbai – 400002, commencing at 5:30 p.m. and concluding at 7:15 p.m. The decisions taken at the meeting are aimed at strengthening the company's governance, compliance, and financial oversight framework, as disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Following the appointments, the company also notified the stock exchange of its updated Key Managerial Personnel (KMP) structure pursuant to Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Board Appointments
The board approved the appointment of Mrs. Sangita Hiren Shukla (DIN: 11647378) as an Additional Independent Director for a period of five years, effective from May 18, 2026 to May 17, 2031, subject to the approval of members at the ensuing Annual General Meeting. Mrs. Shukla is a highly experienced academician and administrator with over 20 years of professional experience in pharmaceutical education, institutional management, and research. She holds a Ph.D. in Pharmaceutical Sciences from Sardar Patel University, an MBA in Human Resource Management, and a Master's degree in Pharmacy (Herbal Drug Technology). She is currently serving as Principal of Indubhai Patel College of Pharmacy & Research Centre and has previously held leadership roles at reputed institutions, ensuring compliance with regulatory authorities such as AICTE, PCI, and GTU. She has over 20 publications to her credit and is not related to any director of the company, nor is she debarred from holding the office of Director by virtue of any SEBI order.
The board also appointed Mr. Krish Piyush Shah as Chief Financial Officer (CFO) effective May 18, 2026. Mr. Shah is a CFA Level III cleared finance professional with two years of hands-on experience in equity derivatives and financial market analysis, with familiarity in private markets. He is skilled in translating market data into actionable investment insights using quantitative and qualitative methods, with a strong foundation in equity valuation, risk management, alternative investments, and portfolio analysis.
Compliance and Audit Roles
To bolster its compliance functions, the company appointed Ms. Khushi Gangwani (ACS: 80518) as Company Secretary and Compliance Officer effective May 18, 2026. Ms. Gangwani is a qualified Company Secretary with over two years of professional experience, with hands-on expertise in matters relating to the Insolvency and Bankruptcy Code, 2016 (IBC), including Corporate Insolvency Resolution Process (CIRP), liquidation proceedings, and personal guarantor cases. She has worked extensively on high-value assignments and listed entity engagements, handling compliance, stakeholder coordination, regulatory filings, and NCLT-related processes.
The board further appointed Mr. Bhaveshkumar Arjunkumar Rawal (FCS: 8812; CP No. 10257), a Practicing Company Secretary, as Secretarial Auditor for a term of five consecutive years commencing from FY 2025-26 to FY 2029-30. Mr. Akash Mehta (Membership No. 168508), a Practicing Chartered Accountant with over 11 years of professional experience in statutory audit, tax advisory, GST compliance, and financial consultancy, was appointed as Internal Auditor for the same five-year term from FY 2025-26 to FY 2029-30.
Summary of Appointments
The following table summarises all key appointments approved at the board meeting:
| Position: | Appointee | Term / Effective Date |
|---|---|---|
| Additional Independent Director | Mrs. Sangita Hiren Shukla | May 18, 2026 – May 17, 2031 (5 years) |
| Chief Financial Officer | Mr. Krish Piyush Shah | Effective May 18, 2026 |
| Company Secretary & Compliance Officer | Ms. Khushi Gangwani | Effective May 18, 2026 |
| Secretarial Auditor | Mr. Bhaveshkumar Arjunkumar Rawal | FY 2025-26 to FY 2029-30 |
| Internal Auditor | Mr. Akash Mehta | FY 2025-26 to FY 2029-30 |
Updated KMP Structure
Following the appointments of Mr. Krish Piyush Shah as CFO and Ms. Khushi Gangwani as Company Secretary & Compliance Officer, the structure of the company's Key Managerial Personnel has been revised. In accordance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Devinsu Trading disclosed the updated KMP details to the stock exchange for the purpose of determining the materiality of events or information and for making requisite disclosures. The updated KMP structure is as follows:
| Sr. No.: | Name of KMP | Designation |
|---|---|---|
| 1 | Mr. Deniis Desai | Whole Time Director |
| 2 | Mr. Krish Piyush Shah | CFO |
| 3 | Ms. Khushi Gangwani | Company Secretary & Compliance Officer |
The disclosure was signed by Mr. Deniis Desai, Whole Time Director (DIN: 02904192), on behalf of Devinsu Trading Limited from Mumbai. The updated KMP information has also been made available on the company's website.
Historical Stock Returns for Devinsu Trading
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
How might Mrs. Sangita Shukla's pharmaceutical education background influence Devinsu Trading's future business strategy or potential pivot toward pharma-related ventures?
Given Ms. Khushi Gangwani's expertise in insolvency and CIRP proceedings, does this appointment signal that Devinsu Trading may be navigating or anticipating any restructuring or regulatory challenges?
Will shareholders approve Mrs. Shukla's appointment as Independent Director at the ensuing AGM, and could any opposition indicate underlying governance concerns at Devinsu Trading?


































